Orphan drugs for the pathogenetic treatment of rаre diseases in the drug registry
Introduction. Despite the high cost of life-threatening rаre diseases, not all expensive drugs for the pathogenetic treatment of orphan diseases are included in the list of vital and essential drugs. Aim. Analysis of drugs for pathogenetic treatment of diseases included in the orphan drugs lists, in...
Main Author: | S. A. Mishinova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Izdatelstvo OKI
2019-04-01
|
Series: | Качественная клиническая практика |
Subjects: | |
Online Access: | https://www.clinvest.ru/jour/article/view/426 |
Similar Items
-
CATEGORY MANAGEMENT IN THE MANAGEMENT OF MINIMUM ASSORTMENT OF THE PHARMACEUTICAL ORGANIZATION
by: I. F. Samoshchenkova, et al.
Published: (2017-05-01) -
Current Problems in Provision of Orphan Drugs and Ways to Solve Them
by: Alexei S. Kolbin, et al.
Published: (2016-09-01) -
Socio-economic and regional aspects of pharmaceutical care to patients with rare diseases in the Omsk region
by: V E Atavin, et al.
Published: (2015-12-01) -
Болезни-сироты и сиротские лекарства
Published: (2018-06-01) -
Health technology assessment: factors affecting the results
by: I. N. Kozhanova
Published: (2021-12-01)